CoChat

Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence

Open access
Aimo, Alberto, Cerbai, Elisabetta, Bartolucci, Gianluca, Adamo, Luigi, Barison, Andrea, Lo Surdo, Giuseppa, Biagini, Stefania, Passino, Claudio, Emdin, Michele · 2020 · Pharmacological Research
Cited by 74

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Myocardial fibrosis is an endogenous response to different cardiac insults that may become maladaptive over time and contribute to the onset and progression of heart failure (HF). Fibrosis is a direct and indirect target of established HF therapies, namely inhibitors of the renin-angiotensin-aldosterone system, but its resilience to therapy warrants a search for novel, more targeted approaches to myocardial fibrosis. Pirfenidone is a drug approved for idiopathic pulmonary fibrosis, a severe form of idiopathic interstitial pneumonias. Pirfenidone is a small synthetic molecule with high oral bioavailability, exerting an antifibrotic activity, but also anti-oxidant and anti-inflammatory effects. These effects have been attributed to the inhibition of several growth factors (in particular transforming growth factor-β, but also platelet-derived growth factor and beta fibroblast growth factor), matrix metalloproteinases, and pro-inflammatory mediators (such as interleukin-1β and tumour necrosis factor-α), and possibly also an improvement of mitochondrial function and modulation of lymphocyte activation. Given the activation of similar profibrotic pathways in lung and heart disease, the crucial role of fibrosis in several cardiac disorders, and the wide spectrum of activity of pirfenidone, this drug has been evaluated with interest as a potential treatment for cardiac disorders. In animal studies, pirfenidone has shown cardioprotective effects across different species and in a variety of models of cardiomyopathy. In the present review we summarize the pharmacological characteristics of pirfenidone and the data from animal studies supporting its cardioprotective effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.phrs.2020.104694

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 74

Metadata

Authors
Aimo, A., Cerbai, E., Bartolucci, G., Adamo, L., Barison, A., Lo Surdo, G., Biagini, S., Passino, C., & Emdin, M.
Venue
Pharmacological Research
Publisher
Elsevier BV
Published
2020-05
Volume
155
Pages
104694
ISSN
1043-6618 (ISSN-L)
OpenAlex
W3005842966
Cited by
74
References
5
FWCI
7.12
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence. https://app.cochat.ai/papers/10.1016/j.phrs.2020.104694
The paper
Aimo, A., Cerbai, E., Bartolucci, G., Adamo, L., Barison, A., Lo Surdo, G., Biagini, S., Passino, C., & Emdin, M. (2020). Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence. Pharmacological Research. https://doi.org/10.1016/j.phrs.2020.104694

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.